{"id":16565,"date":"2018-05-15T12:02:10","date_gmt":"2018-05-15T04:02:10","guid":{"rendered":"http:\/\/biopioneer.com.tw\/?p=16565"},"modified":"2022-07-20T16:44:29","modified_gmt":"2022-07-20T08:44:29","slug":"anti-egfrviii-l8a4-%e8%b2%a8%e8%99%9fab00184-1-1","status":"publish","type":"post","link":"http:\/\/biopioneer.com.tw\/?p=16565","title":{"rendered":"Anti-EGFRvIII [L8A4] | Absoluteantibody\u8ca8\u865fAb00184-1.1"},"content":{"rendered":"

Fc Silent\u2122 Antibodies: Turning down the background noise<\/strong> \u53ea\u8981<\/strong>\u8a0a<\/strong>\u865f\u4e0d\u8981\u96dc<\/strong>\u8a0a (Engineered Fc Domain)<\/strong><\/p>\n

Anti-EGFRvIII [L8A4]<\/strong><\/p>\n

Absoluted Antibody \u63d0\u4f9b\u4e00\u7cfb\u5217\u6297\u9ad4\u5546\u54c1\uff0c\u5176\u4e2dFc Silent\u2122 Antibodies\u7cfb\u5217\uff1b\u80fd\u6709\u6548\u964d\u4f4e\u975e\u7279\u7570\u6027Fc\u7d50\u5408\u3002Fc Silent\u2122\u6280\u8853\uff0c\u70ba\u61c9\u7528\u751f\u7269\u5de5\u7a0b\u6280\u8853\uff0c\u5c07Fc receptors (Fc\u03b3R, FcR)\u9ede\u7a81\u8b8a\uff0c\u9032\u800c\u4e2d\u6b62\u6297\u9ad4\u8207ADCC\u7684\u529f\u80fd\uff1b\u6709\u6548\u964d\u4f4eFc\u6240\u9020\u6210\u7684\u80cc\u666f\u8a0a\u865f\u3002Fc Silent\u2122\u6297\u9ad4\u61c9\u7528\u65bc\u514d\u75ab\u7d30\u80de\u6642flow cytometry\u3001immunohistochemistry (IHC)\u8cc7\u6599\u986f\u793a\uff0c\u6709\u6548\u964d\u4f4e\u975e\u7279\u7570\u6027\u4e4bFc\u7d50\u5408\uff0c\u6240\u9020\u6210\u7684\u80cc\u666f\u503c\u3002(\u8a02\u8cfc\u6297\u9ad4\u524d\uff0c\u8acb\u78ba\u8a8d\u9078\u64c7\u6297\u9ad4\u662f\u5426\u6709Fc Silent\u2122\u4fee\u98fe\u6a19\u8a8c)\u3002<\/p>\n

\u7522\u54c1\u4ecb\u7d39<\/strong> Anti-EGFRvIII [L8A4] \u00a0| <\/strong>\u8ca8\u865f<\/strong>Ab00184-1.1<\/strong><\/a><\/span><\/p>\n

Description:\u00a0<\/strong>Recombinant monoclonal antibody to EGFRvIII. Manufactured using AbAb\u2019s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma L8A4.
\nSpecies and Isotype:\u00a0<\/strong>Mouse IgG1, kappa
\nClone Number:\u00a0<\/strong>L8A4
\nUniProt Accession Number of Target Protein:\u00a0<\/strong>P00533
\nAlternative Name(s) of Target:\u00a0<\/strong>Epidermal Growth Factor Receptor variant III
\nPublished Application(s):\u00a0<\/strong>IF; IHC; Biacore; WB; ELISA; FC
\nPublished Species Reactivity:\u00a0<\/strong>Human
\nImmunogen:\u00a0<\/strong>Pep 3-KLH (Pep 3 is a 14-amino acid peptide corresponding to the predicted amino acid sequence at the fusion junction and KLH stands for keyhole limpet hemocyanin) at da 40 and 103, HC2 20 d2 cells at day 1, 25, 74, 87. And fusion with the nonimmunoglobulin-secreting Kearney variant of P3X63\/Ag8.653.
\nSpecificity:\u00a0<\/strong>Binds EGFRvIII, a mutated form of EGFR, plays a prominent role in tumorigenesis.
\nApplication Notes:\u00a0<\/strong>This antibody can be used to detect EGFRvIII, a mutated EGFR variant, in immunohistochemical staining, Western Blot, ELISA and flow-cytometry. Chou et al (2016, PMID: 27825958) used this antibody to detect EGFRvIII in acetone and PFA fixed sections by fluorescent immunohistochemistry.
\nAntibody First Published in:\u00a0<\/strong>
\nWikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995 Jul 15;55(14):3140-8.\u00a0PMID:7606735<\/a>\u00a0Note on publication:\u00a0<\/strong>Describes the preparation anti human EGFRvIII antibody by long-termimmunization protocols using the EGFRvIII-specific synthetic peptide and the intact variant. Identified using ELISA, Western blot, flow cytometry, and immunohistochemistry techniques.<\/p>\n

Purification:\u00a0<\/strong>Protein A affinity purified<\/p>\n

Supplied in:\u00a0Bulk size:\u00a0<\/b>PBS only.\u00a0Standard size:\u00a0<\/b>PBS with 0.02% Proclin 300.<\/div>\n

Storage Recommendation:\u00a0<\/strong>Store at 4\u00b0C for up to 3 months. For longer term storage aliquot into small volumes and store at -20\u00b0C
\nConcentration:\u00a0<\/strong>See vial label.<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Fc Silent\u2122 Antibodies: Turning down the background nois […]<\/p>\n","protected":false},"author":3,"featured_media":3519,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[136],"tags":[2744],"_links":{"self":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/16565"}],"collection":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16565"}],"version-history":[{"count":3,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/16565\/revisions"}],"predecessor-version":[{"id":16570,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/16565\/revisions\/16570"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/3519"}],"wp:attachment":[{"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16565"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}